Andrographis paniculata is NOT recommended for treating dengue fever
There is no guideline support or clinical evidence demonstrating that Andrographis paniculata improves morbidity, mortality, or quality of life in dengue patients. While laboratory studies show in vitro antiviral activity, this has not translated into proven clinical benefit for dengue infection.
Evidence Analysis
What the Guidelines Say About Dengue Treatment
The available clinical guidelines 1, 2 focus on:
- Supportive care as the mainstay of dengue management
- Diagnostic testing (PCR within 7 days, IgM after 5-7 days)
- Monitoring for complications (hemorrhagic fever, shock syndrome, cardiac involvement)
- No specific antiviral therapy is recommended
Notably, none of the dengue-specific guidelines mention Andrographis paniculata as a treatment option 1, 2.
Where Andrographis IS Mentioned
Andrographis paniculata appears only in guidelines for the common cold and acute rhinosinusitis—not dengue 3. Specifically:
- The 2020 European Position Paper states that "Andrographis paniculata SHA-10 extract have significant impact on symptoms of common cold without important adverse events" 3
- This is for upper respiratory tract infections, not arboviral diseases
The Laboratory Research Gap
Recent research studies 4, 5, 6, 7, 8, 9 demonstrate:
- In vitro antiviral activity against dengue virus in cell lines (EC50 ~21-23 μM for andrographolide) 5
- Post-infection stage activity through mechanisms involving GRP78 and unfolded protein response 7
- Molecular docking studies showing binding to NS2B-NS3 protease 8, 9
However, these are exclusively laboratory findings with no clinical trial data in dengue patients. The 2024 review 6 acknowledges that while Andrographis paniculata shows "promising effects in both in vitro and in vivo studies," it has not undergone clinical trials for dengue.
Critical Clinical Distinction
The 2025 COVID-19 meta-analysis 10 of Andrographis products in 660 patients found:
- No significant improvement in fever resolution (RR 1.12; 95%CI 0.90-1.38)
- No significant improvement in cough resolution (RR 0.98; 95%CI 0.74-1.31)
- No significant reduction in CRP or IL-6 levels
- Mild adverse events including liver enzyme elevations
This demonstrates that even when Andrographis reaches clinical trials for viral infections, benefits are not consistently demonstrated.
Clinical Management Algorithm for Dengue
Instead of unproven herbal therapies, focus on:
- Early recognition of dengue (fever + headache, retro-orbital pain, myalgia, arthralgia, rash) 1
- Diagnostic confirmation (PCR if ≤7 days from onset; IgM if >7 days) 2
- Risk stratification for severe dengue (hemorrhagic fever, shock syndrome, cardiac complications) 11, 1
- Supportive care:
- Fluid management
- Antipyretics (avoid NSAIDs due to bleeding risk)
- Monitoring platelet counts and hematocrit
- Semi-recumbent positioning if hemodynamically stable 12
- Monitor for cardiac complications (12-50% in hospitalized patients, including myocarditis, arrhythmias, pericarditis) 11
Common Pitfalls to Avoid
- Do not delay proven supportive care while pursuing unvalidated herbal remedies
- Do not assume in vitro activity translates to clinical benefit—this is a fundamental error in evidence interpretation
- Do not confuse common cold data with dengue data—these are entirely different disease processes
- Monitor for hepatotoxicity if patients self-administer Andrographis products 10
The absence of Andrographis paniculata from any dengue-specific guideline, combined with lack of clinical trial evidence in dengue patients, makes it impossible to recommend for this indication despite promising laboratory findings.